August 25th, 2020
Harvard University, AbbVie form research alliance to address emergent viral diseases
Commitment of $30M from AbbVie supports research collaboration with Harvard Medical School to advance development of therapeutics
News All News
Press Contact: Kirsten Mabry | (617) 495-4157
Tag: Hms
September 28th, 2016
Wyss Institute launches ReadCoor to commercialize 3D in situ gene sequencing technology
New startup will leverage a method for simultaneously sequencing and mapping thousands of RNAs within cells and tissues to advance development of diagnostics and discover new drug targets
December 16th, 2015
No sharks in these waters
Two emerging life-science ventures draw a crowd and elicit substantive expert feedback at “Guppy Tank” event.
September 16th, 2014
Blavatnik Biomedical Accelerator success story: new hope for neurodegenerative diseases
Professors Dan Finley and Randy King are poised to change the future for those who suffer from neurodegenerative diseases. With the help of OTD’s Biomedical Accelerator, they were able to build on this foundation and advance the frontiers of science and healthcare.
July 15th, 2013
Ipsen announce a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases
Paris (France), 15 July 2013 - Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it
has initiated a research and development collaboration on novel engineered botulinum toxins
with Harvard Medical School (Harvard).
Under the terms of the agreement, Ipsen will fund Harvard research for at least three years
with the aim to discover, evaluate and develop novel engineered recombinant botulinum
toxins for the treatment of serious neurologic diseases.